Correlation Between Pmv Pharmaceuticals and Entera Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pmv Pharmaceuticals and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pmv Pharmaceuticals and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pmv Pharmaceuticals and Entera Bio, you can compare the effects of market volatilities on Pmv Pharmaceuticals and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pmv Pharmaceuticals with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pmv Pharmaceuticals and Entera Bio.

Diversification Opportunities for Pmv Pharmaceuticals and Entera Bio

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Pmv and Entera is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Pmv Pharmaceuticals and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and Pmv Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pmv Pharmaceuticals are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of Pmv Pharmaceuticals i.e., Pmv Pharmaceuticals and Entera Bio go up and down completely randomly.

Pair Corralation between Pmv Pharmaceuticals and Entera Bio

Given the investment horizon of 90 days Pmv Pharmaceuticals is expected to under-perform the Entera Bio. But the stock apears to be less risky and, when comparing its historical volatility, Pmv Pharmaceuticals is 1.87 times less risky than Entera Bio. The stock trades about -0.15 of its potential returns per unit of risk. The Entera Bio is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  218.00  in Entera Bio on December 28, 2024 and sell it today you would lose (36.00) from holding Entera Bio or give up 16.51% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Pmv Pharmaceuticals  vs.  Entera Bio

 Performance 
       Timeline  
Pmv Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Pmv Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Entera Bio 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pmv Pharmaceuticals and Entera Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pmv Pharmaceuticals and Entera Bio

The main advantage of trading using opposite Pmv Pharmaceuticals and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pmv Pharmaceuticals position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.
The idea behind Pmv Pharmaceuticals and Entera Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules